Inozyme Pharma Q1 EPS $(0.38) Misses $(0.36) Estimate
Portfolio Pulse from Benzinga Newsdesk
Inozyme Pharma (NASDAQ:INZY) reported Q1 earnings with losses of $(0.38) per share, missing the consensus estimate of $(0.36) by 5.56%. This represents a 5% improvement over the previous year's losses of $(0.40) per share.
May 07, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Inozyme Pharma reported a Q1 EPS loss of $(0.38), missing estimates by 5.56% but showing a 5% year-over-year improvement.
Missing the earnings estimate typically results in negative investor sentiment in the short term, leading to potential stock price decline. However, the improvement over last year's losses may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100